Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics (NASDAQ: VKTX) was one of the hottest biotech stocks of 2024; its shares soared last year following ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

CompanyOverview|NASDAQ:VKTX] Viking Therapeutics Inc. (NASDAQ: VKTX) reported earnings after the market closed on Apr. 23.

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports.

Shares of Viking Therapeutics (NASDAQ: VKTX) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts. Seedhouse doesn't beat around the bush: "Our thesis is ...